RI Hospital Study: Graft Occlusion in Hemodialysis Patients

RI Hospital Study:
Graft Occlusion in Hemodialysis Patients

Rhode Island Hospital is seeking patients to participate in a phase I trial with plasmin to evaluate the safety and to select the doses of phase II in patients with hemodialysis graft occlusion.

Plasmin is a direct thrombolytic agent developed as a potential therapeutic agent for the treatment of hemodialysis patients with thrombosed arterio-venous shunts.

Patients or individuals interested in taking part in this trial should be on chronic hemodialysis with a graft that now is occluded or has gone down.

For more information, or to refer a patient, please contact the vascular interventional radiology department at 401-444-5194.